ReviewNanomaterials (Basel, Switzerland)2020
Stealth Coating of Nanoparticles in Drug-Delivery Systems.
Review in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
153 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.Theranostics · 2021Pooled it
- Engineering metal-organic framework-based smart porous nanoplatforms for targeted therapy and theranostic applications.Smart molecules : open access · 2026Review
- Overcoming hepatic tropism: Precision engineering of lipid nanoparticles for extrahepatic RNA delivery.Materials today. Bio · 2026Review
- Nanoparticles for Drug Delivery: Design, Mechanisms, and Clinical Translation.Molecules (Basel, Switzerland) · 2026Review
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Layer by Layer Engineered Lipid-Based Nanocarriers for Therapeutic Delivery and Next-Generation Design.Pharmaceutics · 2026Review
- Surface charge engineering shields extracellular vesicles from plasma protein corona to enable systemic extrahepatic targeting.Materials today. Bio · 2026Article
- Rationally Designed Zwitterionic Peptides Improve siRNA Delivery of Cationic Diblock Copolymer-Based Nanoparticle Drug-Delivery Systems.ACS applied nano materials · 2026Article
- Engineering of Glioblastoma-Derived Biomimetic Vesicles and Their Structural and Molecular Features.Advanced healthcare materials · 2026Article
- Nanoadjuvant-integrated organic biomaterials for immune engineering: Mechanisms, design strategies, and translational applications.Materials today. Bio · 2026Review
- Nanoparticle Strategies for Bone Metastasis Immunotherapy: Targeting, Immune Reprogramming and Combination Therapy.Pharmaceutics · 2026Review
- Upconverting Nanoparticles Functionalized with Protein-Gold Nanoclusters and Chlorin e6 for Near-Infrared-Activated Photodynamic Therapy.Nanomaterials (Basel, Switzerland) · 2026Article
- Improving photodynamic therapy efficacy in bladder cancer using polymer micelle-encapsulated pheophorbide a.Translational oncology · 2026Article
- Magnetic nanoparticles for cancer theranostics.Biomedical physics & engineering express · 2026Review
- Conjugable, Antifouling, and Non-immunogenic Coatings for Gold Nanoparticles by Multivalent Grafting of Azide-Bearing Polyoxazoline Brushes.Langmuir : the ACS journal of surfaces and colloids · 2026Article
- Green and chemical synthesis of PEGylated ginger gold nanoparticles for neuro-nanomedicine applications.Scientific reports · 2026Article
- Tumor radiosensitization with gold nanoparticles: evolving strategies to improve tumoral gold uptake and catalyze future clinical translation.ACS nano medicine · 2026Article
- AFM-Based Single-Molecule Force Spectroscopy of PEG-Anti-PEG Antibody Interactions.ACS applied bio materials · 2026Article
- Surface Modification of Zinc Undecylenate with Nanoparticle Fluconazole Using Low-Pressure RF Plasma-Assisted CVD: A New Generation Antifungal Compound.AAPS PharmSciTech · 2026Article
- Nature-Inspired Alternatives to PEG for Next-Generation Long-Circulating Nanocarriers.International journal of nanomedicine · 2026Review
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Nanoparticles (NPs) have emerged as a powerful drug-delivery tool for cancer therapies to enhance the specificity of drug actions, while reducing the systemic side effects. Nonetheless, NPs interact massively with the surrounding physiological environments including plasma proteins upon administration into the bloodstream. Consequently, they are rapidly cleared from the blood circulation by the mononuclear phagocyte system (MPS) or complement system, resulting in a premature elimination that will cause the drug release at off-target sites. By grafting a stealth coating layer onto the surface of NPs, the blood circulation half-life of nanomaterials can be improved by escaping the recognition and clearance of the immune system. This review focuses on the basic concept underlying the stealth behavior of NPs by polymer coating, whereby the fundamental surface coating characteristics such as molecular weight, surface chain density as well as conformations of polymer chains are of utmost importance for efficient protection of NPs. In addition, the most commonly used stealth polymers such as poly(ethylene glycol) (PEG), poly(2-oxazoline) (POx), and poly(zwitterions) in developing long-circulating NPs for drug delivery are also thoroughly discussed. The biomimetic strategies, including the cell-membrane camouflaging technique and CD47 functionalization for the development of stealth nano-delivery systems, are highlighted in this review as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.